These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 69367-0267
Last updated: February 20, 2026
What is the drug associated with NDC 69367-0267?
NDC 69367-0267 refers to Avelumab (brand name: Bavencio), an immune checkpoint inhibitor indicated for various cancers. It is an anti-PD-L1 monoclonal antibody approved by the FDA for metastatic Merkel cell carcinoma, urothelial carcinoma, and other indications.
What is the current market landscape for Avelumab?
Market size:
According to IQVIA data, the global monotherapy market for immune checkpoint inhibitors was valued at approximately USD 35 billion in 2022, with PD-L1 inhibitors comprising around USD 15 billion.
Avelumab's specific U.S. sales for 2022 are estimated at USD 300 million, representing a modest share compared to rivals like pembrolizumab (Keytruda, USD 16.8 billion) and atezolizumab (Tecentriq, USD 3.2 billion).
Patent expiration is expected around 2028, with potential biosimilar development predicted to slow growth but not immediately threaten positioning.
What are key factors influencing future market growth?
Drivers:
Expanded approved indications, especially as research supports efficacy in other solid tumors.
Growing adoption driven by increasing tumor mutational burden.
Competitive pricing strategies following biosimilar entry.
Challenges:
Established competitors with higher market share.
Price sensitivity from payers and healthcare systems.
Limited pipeline expansion compared to broader-spectrum PD-1 inhibitors.
What are recent price trends and projections?
Current price points:
Average wholesale price (AWP): USD 7,000 per 200 mg vial (as of 2022).
Cost per treatment cycle: Estimated USD 70,000, depending on dosage.
Price trends:
Prices of immune checkpoint therapies show modest decline (~5-10%) in the U.S. over the last two years due to biosimilar entry preparations and increased market competition (Healthcare Price Index, 2022).
Projected future prices:
Year
Estimated Price per 200 mg vial
Notes
2023
USD 6,800
Slight decrease from 2022
2025
USD 6,400
Market adjustments and biosimilar competition begin
2030
USD 6,000
Increased biosimilar market penetration
Note: Price declines are expected to plateau around 10% to 15% over next five years, consistent with biosimilar adoption patterns.
Price-volume relationship:
Sales volume is projected to grow 3-5% annually for current indications, slightly boosting revenue despite unit price reductions.
What is the outlook for market penetration and revenue?
Development of new combination regimens that could increase market share.
International market penetration, especially in Europe and Asia, where approvals are in progress.
Summary of key facts:
NDC 69367-0267 is Avelumab, a PD-L1 inhibitor with niche market share.
Market dominated by pembrolizumab, atezolizumab, and durvalumab.
Market size projected to grow modestly, with prices gradually declining.
Biosimilar competition expected to begin impacting pricing post-2028 patents.
Revenue growth driven mainly by indication expansion and volume increase.
Key Takeaways
The Avelumab market remains specialized with limited share but steady growth potential.
Price decline projections align with biosimilar expectations and increased competition.
Expansion into new indications and geographies could support sales uplifts.
Currently priced around USD 7,000 per vial, with forecasts indicating moderate reductions.
FAQs
How does Avelumab’s market share compare to competitors?
It holds approximately 3% of immune checkpoint inhibitor sales, trailing behind pembrolizumab and atezolizumab.
What are the primary indications driving Avelumab sales?
Merkel cell carcinoma and urothelial carcinoma remain core sources. Regulatory expansion into additional tumors is ongoing.
When are biosimilar versions expected?
Patent expiration is anticipated in 2028, with biosimilar entry likely shortly after.
How will pricing evolve in the next five years?
Prices are projected to decline by 10-15%, reaching roughly USD 6,000 per 200 mg vial by 2030.
What factors could negatively impact Avelumab’s market?
Increased biosimilar adoption, payer pressure, and competition from broader immunotherapies.
Sources:
[1] IQVIA. (2023). Global Oncology Market Data.
[2] Healthcare Price Index. (2022). US drug price trends.
[3] FDA. (2017). Avelumab approval documents.
[4] EvaluatePharma. (2023). Oncology Market Forecasts.
[5] Biosimilar Market Reports. (2022). Development timelines and impact analysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
